BMS/Thermocore pact for vulnerable plaque
This article was originally published in The Gray Sheet
Executive Summary
Bristol-Myers Squibb gains worldwide development, manufacturing and commercialization rights to Thermocore intracoronary thermographic catheter system technology designed to detect vulnerable plaque by mapping temperature variations inside coronary arteries. Rupture of vulnerable plaque is a prime cause of heart attack. Initial clinical trials will focus on assessing the prognostic value of the device, according to BMS. During a vulnerable plaque summit at the May CRT 2004 conference in Washington, D.C., participants generally agreed that no accurate imaging tools currently exist to detect vulnerable plaque 1"The Gray Sheet" May 10, 2004, p. 4)...
You may also be interested in...
DES For Vulnerable Plaque: Consensus Elusive With Current Imaging Tools
Drug-eluting stents should not be viewed as the definitive treatment for vulnerable plaque, according to David Holmes, MD, Mayo Clinic
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.